Since its inception in 2008, the Clinical Trials on Alzheimer’s Disease (CTAD) conference has established itself as the premier global meeting exclusively dedicated to clinical trials in Alzheimer’s Disease.
Building on the success of the CTAD China Workshop held in Shanghai in September 2025, we are proud to announce the next chapter of this initiative: the CTAD 2027 Asia Symposium, to be held on January 17–18, 2027, in Singapore.
Singapore, as one of the world’s foremost hubs for biomedical research, innovation and international collaboration, provides the ideal setting for this workshop that will bring together leading researchers, clinicians and industry partners from across Asia — alongside distinguished experts from Europe and the United States.
The program will feature focused discussions on the most critical and rapidly evolving topics in AD research, including newly approved therapies and real-world experience, emerging biomarkers and diagnostic tools, cutting-edge imaging technologies in AD clinical trials, and new therapeutic avenues beyond amyloid-clearing treatments.
Breakthrough translational research and innovative approaches to clinical trial design and execution in the Asia context will also be central to the agenda.
Abstract submissions from leading research teams across the Asia region are warmly invited, further enriching the exchange of ideas at this landmark event.
As attendance is limited, participation will be reserved for a select group of distinguished experts. We look forward to welcoming you to Singapore for what promises to be a pivotal step forward in advancing Alzheimer’s research across the Asia region.